{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:30:36Z","timestamp":1788280236161,"version":"build-2803163510"},"reference-count":89,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/mjt.0b013e31824a0ed7","type":"journal-article","created":{"date-parts":[[2012,9,13]],"date-time":"2012-09-13T16:00:51Z","timestamp":1347552051000},"page":"419-435","source":"Crossref","is-referenced-by-count":9,"title":["Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin\u2013Angiotensin\u2013Aldosterone System Antagonists"],"prefix":"10.1097","volume":"21","author":[{"given":"Gregg","family":"Lanier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedar","family":"Sankholkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210202","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":". The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"R2-14-20210202","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":". 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"R3-14-20210202","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","article-title":". ACCFAHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.","volume":"57","author":"Aronow","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R4-14-20210202","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","article-title":"ACCAHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of CardiologyAmerican Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).","volume":"46","author":"Hunt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R5-14-20210202","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/CIRCULATIONAHA.109.192064","article-title":". 2009 focused update: ACCFAHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology FoundationAmerican Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation"},{"key":"R6-14-20210202","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"R7-14-20210202","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(07)60242-6","article-title":"Renin-angiotensin system and cardiovascular risk.","volume":"369","author":"Schmieder","year":"2007","journal-title":"Lancet"},{"key":"R8-14-20210202","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":". A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly.","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"R9-14-20210202","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","article-title":". Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.","volume":"25","author":"Turnbull","year":"2007","journal-title":"J Hypertens"},{"key":"R10-14-20210202","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":". Telmisartan, ramipril, or both in patients at high risk for vascular events.","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R11-14-20210202","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":". Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R12-14-20210202","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":". Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"R13-14-20210202","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":". Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.","volume":"165","author":"Turnbull","year":"2005","journal-title":"Arch Intern Med"},{"key":"R14-14-20210202","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":". Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"R15-14-20210202","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":". Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R16-14-20210202","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":". In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.","volume":"336","author":"Ojima","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R17-14-20210202","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1751-7176.2010.00425.x","article-title":". The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.","volume":"13","author":"Bakris","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R18-14-20210202","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/HYPERTENSIONAHA.110.163402","article-title":". Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.","volume":"57","author":"White","year":"2011","journal-title":"Hypertension"},{"key":"R19-14-20210202","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1751-7176.2011.00482.x","article-title":". Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.","volume":"13","author":"Sica","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R20-14-20210202","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CRD.0b013e31822e9ba3","article-title":"Azilsartan: a newly approved angiotensin II receptor blocker.","volume":"19","author":"Lam","year":"2011","journal-title":"Cardiol Rev"},{"key":"R21-14-20210202","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1345\/aph.1Q468","article-title":"Azilsartan medoxomil: a new angiotensin ii receptor antagonist for treatment of hypertension.","volume":"45","author":"Baker","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R22-14-20210202","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1592\/phco.29.2.193","article-title":"Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.","volume":"29","author":"Sanoski","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R23-14-20210202","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacc.2007.10.027","article-title":"Renin inhibition in hypertension.","volume":"51","author":"Gradman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R24-14-20210202","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/hrt.76.3_Suppl_3.18","article-title":"Is there a link between the circulating renin-angiotensin system and coronary disease A buoyant view.","volume":"76","author":"Alderman","year":"1996","journal-title":"Heart"},{"key":"R25-14-20210202","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/CRD.0b013e31814852a4","article-title":"Aliskiren: an oral renin inhibitor for the treatment of hypertension.","volume":"15","author":"Lam","year":"2007","journal-title":"Cardiol Rev"},{"key":"R26-14-20210202","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R27-14-20210202","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.107.750745","article-title":". Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.","volume":"119","author":"Schmieder","year":"2009","journal-title":"Circulation"},{"key":"R28-14-20210202","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.0000156466.02908.ED","article-title":"Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.","volume":"111","author":"Gradman","year":"2005","journal-title":"Circulation"},{"key":"R29-14-20210202","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.HYP.0000101688.17370.87","article-title":"Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.","volume":"42","author":"Stanton","year":"2003","journal-title":"Hypertension"},{"key":"R30-14-20210202","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/HJH.0b013e3282f3ad9a","article-title":". Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.","volume":"26","author":"Andersen","year":"2008","journal-title":"J Hypertens"},{"key":"R31-14-20210202","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3317\/jraas.2007.028","article-title":". Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.","volume":"8","author":"Uresin","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"R32-14-20210202","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/jhh.2009.107","article-title":"Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.","volume":"24","author":"Duprez","year":"2010","journal-title":"J Hum Hypertens"},{"key":"R33-14-20210202","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":". Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.","volume":"25","author":"Villamil","year":"2007","journal-title":"J Hypertens"},{"key":"R34-14-20210202","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1185\/03007990902804158","article-title":". Antihypertensive efficacy and tolerability of aliskirenhydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone.","volume":"25","author":"Blumenstein","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R35-14-20210202","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1524-6175.2007.06614.x","article-title":"Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.","volume":"9","author":"Drummond","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R36-14-20210202","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1185\/03007990902785845","article-title":"3rd, Trenkwalder P, Hollanders G, Zhao Y, Liao W. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension.","volume":"25","author":"Littlejohn","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R37-14-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"R38-14-20210202","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/ndt\/gfn721","article-title":". Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.","volume":"24","author":"Parving","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R39-14-20210202","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurheartj\/ehq522","article-title":". Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.","volume":"32","author":"Solomon","year":"2011","journal-title":"Eur Heart J"},{"key":"R40-14-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":". Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"key":"R41-14-20210202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/VHRM.S15541","article-title":"A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.","volume":"7","author":"Siragy","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"R42-14-20210202","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1751-7176.2010.00352.x","article-title":". Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.","volume":"12","author":"White","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R43-14-20210202","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"R44-14-20210202","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":". Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"R45-14-20210202","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1056\/NEJMsa0903829","article-title":"Shattuck Lecture. The hypertension paradox-more uncontrolled disease despite improved therapy.","volume":"361","author":"Chobanian","year":"2009","journal-title":"N Engl J Med"},{"key":"R46-14-20210202","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1185\/03007990802319364","article-title":"2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations.","volume":"24","author":"Brixner","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R47-14-20210202","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.HYP.0000200702.76436.4b","article-title":"Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals.","volume":"47","author":"Okonofua","year":"2006","journal-title":"Hypertension"},{"key":"R48-14-20210202","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.amjhyper.2007.02.017","article-title":"Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.","volume":"20","author":"Weir","year":"2007","journal-title":"Am J Hypertens"},{"key":"R49-14-20210202","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","article-title":"Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.","volume":"62","author":"Sica","year":"2002","journal-title":"Drugs"},{"key":"R50-14-20210202","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/HYPERTENSIONAHA.109.131300","article-title":"Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.","volume":"54","author":"Calhoun","year":"2009","journal-title":"Hypertension"},{"key":"R51-14-20210202","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","article-title":". Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.","volume":"47","author":"Ernst","year":"2006","journal-title":"Hypertension"},{"key":"R52-14-20210202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/01.HYP.0000103632.19915.0E","article-title":"Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability.","volume":"43","author":"Carter","year":"2004","journal-title":"Hypertension"},{"key":"R53-14-20210202","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.clinthera.2011.10.007","article-title":"Azilsartan medoxomil: a new Angiotensin receptor blocker.","volume":"33","author":"Zaiken","year":"2011","journal-title":"Clin Ther"},{"key":"R54-14-20210202","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":". Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"R55-14-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9149(96)00781-3","article-title":"Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group.","volume":"79","author":"Gradman","year":"1997","journal-title":"Am J Cardiol"},{"key":"R56-14-20210202","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.clinthera.2007.03.018","article-title":". Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.","volume":"29","author":"Philipp","year":"2007","journal-title":"Clin Ther"},{"key":"R57-14-20210202","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jash.2011.02.008","article-title":"Initial combination therapy with amlodipinevalsartan compared with monotherapy in the treatment of hypertension.","volume":"5","author":"Philipp","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"R58-14-20210202","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1345\/aph.1P663","article-title":". Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study).","volume":"45","author":"Lins","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R59-14-20210202","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12325-010-0099-1","article-title":"Real-life safety and effectiveness of amlodipinevalsartan combination in the treatment of hypertension.","volume":"28","author":"Chazova","year":"2011","journal-title":"Adv Ther"},{"key":"R60-14-20210202","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clinthera.2008.04.002","article-title":"The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.","volume":"30","author":"Chrysant","year":"2008","journal-title":"Clin Ther"},{"key":"R61-14-20210202","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.jhh.1002140","article-title":". Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.","volume":"21","author":"Fogari","year":"2007","journal-title":"J Hum Hypertens"},{"key":"R62-14-20210202","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1586\/ecp.10.141","article-title":"Telmisartan for the reduction of cardiovascular morbidity and mortality.","volume":"4","author":"Verdecchia","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R63-14-20210202","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":". Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"R64-14-20210202","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0002-8703(03)00082-6","article-title":"Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study.","volume":"145","author":"Jorgensen","year":"2003","journal-title":"Am Heart J"},{"key":"R65-14-20210202","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/11204880-000000000-00000","article-title":"Telmisartanamlodipine: single-pill combination in hypertension.","volume":"10","author":"Moen","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"R66-14-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1751-7176.2009.00098.x","article-title":"3rd, Majul CR, Olvera R, et al.. Results of treatment with telmisartan-amlodipine in hypertensive patients.","volume":"11","author":"Littlejohn","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R67-14-20210202","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1751-7176.2011.00468.x","article-title":"Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study.","volume":"13","author":"Neldam","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R68-14-20210202","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/erc.10.143","article-title":"Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results.","volume":"8","author":"Oigman","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R69-14-20210202","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lfs.2009.11.020","article-title":"Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.","volume":"86","author":"Ferrario","year":"2010","journal-title":"Life Sci"},{"key":"R70-14-20210202","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-010-6278-0","article-title":"Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.","volume":"25","author":"Siragy","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"R71-14-20210202","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1586\/14779072.6.3.305","article-title":"Aliskiren-hydrochlorothiazide combination for the treatment of hypertension.","volume":"6","author":"Chrysant","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R72-14-20210202","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2174\/1874192401105010006","article-title":"Efficacy of aliskirenhydrochlorothiazide combination for the treatment of hypertension: a meta-analytical approach.","volume":"5","author":"Morgado","year":"2011","journal-title":"Open Cardiovasc Med J"},{"key":"R73-14-20210202","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1751-7176.2011.00438.x","article-title":". Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.","volume":"13","author":"White","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R74-14-20210202","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1751-7176.2010.00418.x","article-title":"Comparison of aliskirenhydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: results of the ACTION study.","volume":"13","author":"Basile","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R75-14-20210202","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/BF03256921","article-title":"Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.","volume":"31","author":"Sica","year":"2011","journal-title":"Clin Drug Investig"},{"key":"R76-14-20210202","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/VHRM.S8175","article-title":"Aliskiren and valsartan combination therapy for the management of hypertension.","volume":"6","author":"Epstein","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"R77-14-20210202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11591970-000000000-00000","article-title":"Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartanHCT combination: a placebo-controlled study.","volume":"11","author":"Drummond","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"R78-14-20210202","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0140-6736(10)62003-X","article-title":"Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.","volume":"377","author":"Brown","year":"2011","journal-title":"Lancet"},{"key":"R79-14-20210202","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1751-7176.2011.00483.x","article-title":". Comparative efficacy and safety of combination aliskirenamlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension.","volume":"13","author":"Black","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R80-14-20210202","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1524-6175.2002.02045.x","article-title":". Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).","volume":"4","author":"Cushman","year":"2002","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R81-14-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinthera.2007.01.007","article-title":"Comparison of valsartanhydrochlorothiazide combination therapy at doses up to 32025 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults.","volume":"29","author":"Pool","year":"2007","journal-title":"Clin Ther"},{"key":"R82-14-20210202","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.clinthera.2005.07.010","article-title":". Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.","volume":"27","author":"Lacourciere","year":"2005","journal-title":"Clin Ther"},{"key":"R83-14-20210202","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clinthera.2005.05.006","article-title":"Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.","volume":"27","author":"Ruilope","year":"2005","journal-title":"Clin Ther"},{"key":"R84-14-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jash.2011.02.007","article-title":". Moderate versus intensive treatment of hypertension using amlodipinevalsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racialethnic subgroups.","volume":"5","author":"Ofili","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"R85-14-20210202","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/erc.10.163","article-title":"Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.","volume":"9","author":"Ram","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R86-14-20210202","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.clinthera.2010.07.008","article-title":"Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.","volume":"32","author":"Oparil","year":"2010","journal-title":"Clin Ther"},{"key":"R87-14-20210202","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1751-7176.2009.00159.x","article-title":"Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension.","volume":"11","author":"Chrysant","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R88-14-20210202","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jash.2011.01.006","article-title":"Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension.","volume":"5","author":"Ferdinand","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"R89-14-20210202","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.2010.650","article-title":"US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.","volume":"303","author":"Egan","year":"2010","journal-title":"JAMA"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201409000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:42:42Z","timestamp":1618036962000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201409000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31824a0ed7","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}